In order to evaluate the safety and efficacy of the hospital atomization preparation Huaxi Guangyi No.1 to be developed, the safety of Guangyi No.1 was used to investigate by acute toxicity test in mice and nasal mucosa irritation test in rat. The efficacy of Guangyi No.1 was used to investigate by pharmacodynamic test for enhancing immune function. The results show that there is no obvious acute toxicity to mice when 0.34 g/mL of the drug solution was given by atomization within 24 hours. There was no obvious irritation of intranasal administration in rats. Aerosolized administration at 0.068 g/mL tended to increase the thymic index of young mice. It can increase the carbon clearance index K and correction index α of macrophages and the levels of WBC and HGB in peripheral blood of immunocompromised mice induced by cyclophosphamide, and increase the value of hemolysin. It is concluded that the maximum dose of Huaxi Guangyi No.1 aerosol administration in mice is 34 g/kg, and there is no obvious irritation of nasal mucosa. The 0.068 g/mL aerosol administration can enhance immune function and can be used to prevent upper respiratory tract infection.